Amgen’s Otezla And BMS’s Sotyktu Battle For Share In Oral Psoriasis Drug Market

Q4 Was First Full Quarter BMS’s TYK2 Inhibitor Was Available

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Amgen and Bristol defended their positions in the post-topical/pre-biologic segment of the psoriasis market during their Q4 earnings calls, now that each company has an oral drug available.

PSORIASIS Text, On Background of Medicaments Composition, Stethoscope, mix therapy drugs doctor flu antibiotic pharmacy medicine medical

Amgen, Inc.’s Otezla was the only branded oral drug available for use in psoriasis patients after topical medicines but before biologics for the inflammatory skin condition until Bristol Myers Squibb Company’s Sotyktu (deucravacitinib) entered the field with US Food and Drug Administration approval in September. Now the companies have their first full quarter of combat behind them and managements’ comments show where each has taken hits in the battle for market share.

Amgen’s EVP of global commercial operations Murdo Gordon said during the company’s 31 January fourth quarter sales and earnings call...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

Scrip-NewProducts (Premium-2): Top 12 Pharma Companies: Pfizer Tops The Leaderboard Again

 
• By Nabil

The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.

Innovent/GenFleet Score China’s First KRAS G12C Inhibitor Approval

 
• By Dexter Jie Yan

The nod will help unlock a national market for the partners’ Dupert (fulzerasib) in which roughly 50,000 people are expected to be newly diagnosed with lung cancer harboring the KRAS G12C mutation in 2025. Meanwhile, two other homegrown rivals are also closing in on marketing clearances in China.

Cagrisema Leads The Charge For 2025

 
• By Elizabeth Cairns

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.  

Small But Mitey: Tarsus To Amp Up Strong Xdemvy Launch

 
• By Alexandra Shimmings

Tarsus Pharmaceuticals is putting more sales and marketing heft behind its novel eyelid disease therapy, Xdemvy, to capitalize on a solid start in a previously untapped market.    

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.